H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)

June 4, 2026 6:40 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $290.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found